Protectins are a family of Specialized pro-resolving mediators (SPMs) (SPMs) biosynthesized from DHA (docosahexaenoic acid, 22:6n-3) via the 15-LOX pathway. Protectin D1 (PD1), also termed neuroprotectin D1 (NPD1) when produced in neural tissue, actively orchestrates inflammatory resolution by halting neutrophil infiltration, promoting Efferocytosis, and shielding neurons from secondary damage. Unlike passive inflammation cessation, protectins are active biochemical signals that switch the immune response from combat mode to repair mode.
Imagine a house fire where the fire brigade has extinguished the flames but broken down doors, smashed windows, and flooded the basement in the process. The protectins are the clean-up crew arriving during the final stages of firefighting — not after the fire is out, but while embers still smoulder. They do three critical jobs simultaneously: (1) they whistle the fire trucks back to the station (stopping more firefighters/neutrophils from showing up and causing collateral damage), (2) they bring in the debris removal teams (macrophages performing efferocytosis), and (3) they erect scaffolding to stabilise walls that were weakened but not destroyed (neuroprotection — preventing secondary neuronal death). The protectins themselves are built from DHA — the omega-3 fatty acid is the raw material, like the steel girders stored in the construction yard. If you haven't been eating enough DHA (fish, algae), the yard is empty, and the clean-up crew has no scaffolding to deploy. In the brain, this becomes especially catastrophic: neurons that survived the initial insult (stroke, trauma, infection) die anyway from the toxic debris left behind, because there's no NPD1 to protect them.
Protectin biosynthesis occurs through a stereospecific enzymatic cascade:
DHA → 17S-hydroperoxy-DHA → 16S,17S-epoxide intermediate → PD1 (10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid)
graph TD
A[DHA in membrane phospholipids] -->|15-LOX| B[17S-HpDHA]
B -->|epoxide intermediate| C[16S,17S-epoxy-DHA]
C -->|hydrolysis| D[Protectin D1 / NPD1]
D -->|binds| E[GPR37 receptor]
E --> F["β-arrestin recruitment"]
E --> G[cAMP modulation]
F --> H[Anti-apoptotic signaling]
G --> H
H --> I["NF-κB suppression"]
H --> J[Bcl-2 upregulation]
H --> K[COX-2 downregulation]
D -->|also binds| L["RORα nuclear receptor"]
L --> M[Anti-inflammatory gene transcription]
D --> N[Enhanced efferocytosis markers]
D --> O[Reduced PMN infiltration]
D --> P[Synaptic protection]
Synthesis pathway:
- 15-LOX (15-lipoxygenase) converts DHA to 17S-hydroperoxy-DHA (17S-HpDHA)
- Epoxide intermediate formation via 16S,17S-epoxy-DHA
- Enzymatic hydrolysis yields PD1, a conjugated triene structure with precise stereochemistry
Receptor signaling:
- GPR37 (orphan G-protein coupled receptor) — primary protectin receptor on neurons, microglia, and leukocytes
- GPR37 activation → β-arrestin recruitment → anti-apoptotic signaling
- Prevents caspase-3 activation
- Upregulates Bcl-2 (anti-apoptotic protein)
- Downregulates COX-2 and pro-inflammatory cytokine production
- RORα (retinoic acid receptor-related orphan receptor alpha) — nuclear receptor for genomic effects
- Transcriptional suppression of NF-κB-dependent genes
- Enhanced expression of anti-inflammatory mediators
Cellular actions:
- Neutrophil regulation:
- Blocks neutrophil transendothelial migration (EC50 ~1-10 nM)
- Reduces CXCL1 and IL-8 chemokine gradients
- Shortens neutrophil lifespan via apoptosis induction
- Efferocytosis enhancement:
- Upregulates C1q, Annexin-1 (ANXA1), and phosphatidylserine recognition on macrophages
- Promotes M2-like macrophage phenotype
- Neuroprotection:
- Prevents oxidative stress-induced neuronal death (potency ~0.1-10 nM)
- Maintains mitochondrial membrane potential
- Reduces excitotoxicity from glutamate
- Preserves synaptic density post-ischemia
Metabolic inactivation:
- SPM metabolic inactivation occurs via oxidation (loss of biological activity)
- Half-life in vivo: ~30-90 minutes (rapid clearance ensures temporal precision)
Protectins are critical for understanding the resolution deficit underlying chronic inflammatory and neurodegenerative diseases. In cPNI, protectin deficiency explains why inflammation persists even after the initial trigger (pathogen, injury) is gone — the "stop signal" is biochemically absent.
Patient populations:
- Neurodegenerative disease (Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis): NPD1 levels are dramatically reduced in hippocampus and cortex. This contributes to uncontrolled neuroinflammation and secondary neuronal loss.
- Post-stroke patients: NPD1 production in peri-infarct zones determines whether surviving neurons recover or undergo delayed apoptosis. Low baseline DHA predicts worse functional outcomes.
- Traumatic stress and PTSD: Hippocampal NPD1 deficiency impairs fear memory extinction and neuroplasticity. Chronic stress depletes DHA stores.
- IBD (Crohn's disease, Ulcerative Colitis): Intestinal protectin levels correlate inversely with disease activity. Resolution failure sustains mucosal damage.
- Dry eye disease and ocular inflammation: Protectins regulate corneal nerve regeneration and tear film homeostasis.
Metamodel connections:
- Metamodel 3 (Netto Toxicity): Low Omega-3 intake → inadequate protectin synthesis → netto toxicity from unresolved inflammation
- Metamodel 5 (Selfish Systems): The Selfish Brain prioritizes DHA for neural protectin synthesis; peripheral tissues suffer resolution deficits when DHA is scarce
- Evolutionary mismatch: Modern diets provide DHA:EPA ratios of ~1:1-3 (or worse, via supplementation imbalance); ancestral intake likely favored higher DHA from brain, marrow, and seafood, ensuring robust protectin synthesis
Biomarkers and thresholds:
- Omega-3 Index <4% (erythrocyte EPA+DHA) correlates with impaired SPM production
- Plasma PD1 levels <0.1 ng/mL suggest resolution incompetence (emerging research cutoff)
- CSF NPD1 is measurable but not yet clinically standardized
Intervention implications:
- Dietary DHA: 1-2 g/day from fatty fish, algae oil, or krill oil (requires 8-12 weeks to saturate membrane phospholipids)
- Avoid oxidative stress: Oxidized DHA cannot form protectins; ensure adequate Vitamin E, Selenium, and Glutathione status
- Address competition: High arachidonic acid (AA) intake from grain-fed meat competes for 15-LOX; favor grass-fed sources or reduce AA:DHA ratio
- Aspirin potentiation: Low-dose aspirin acetylates COX-2, enabling synthesis of Aspirin-triggered resolvins and protectins (ATPs) — an orthogonal pathway that may augment resolution
- Inflammation timing matters: Protectins are synthesized during the resolution phase (12-48 hours post-injury). Early anti-inflammatory intervention (e.g., high-dose NSAIDs) may paradoxically block protectin biosynthesis.
- Protectin D1 (PD1) = neuroprotectin D1 (NPD1) — same molecule, context-dependent naming
- Derived from DHA (22:6n-3) via stereospecific 15-LOX pathway; requires molecular oxygen
- Acts at nanomolar concentrations (EC50 ~1-10 nM for most biological effects)
- Primary receptor: GPR37 (G-protein coupled); secondary: RORα (nuclear receptor)
- Highly enriched in neural tissue, retina, and testes (tissues with high DHA content)
- Blocks neutrophil infiltration at concentrations 100-1000× lower than NSAIDs
- Promotes efferocytosis by upregulating macrophage "eat-me" signal recognition
- Half-life in vivo: 30-90 minutes (rapid synthesis and clearance for temporal control)
- Deficient in Alzheimer's brain tissue (hippocampus shows 70-90% reduction vs. age-matched controls)
- Requires adequate dietary Omega-3 intake; conversion from ALA (alpha-linolenic acid) is inefficient (<5% in humans)
- Production is impaired by oxidative stress, chronic inflammation, and FADS2 polymorphisms (which reduce DHA synthesis from EPA)
- Aspirin acetylation of COX-2 can generate aspirin-triggered protectins (ATPs), expanding the resolution toolkit
- DHA — biosynthetic precursor; membrane phospholipid stores determine protectin synthesis capacity
- 15-LOX — enzyme catalyzing first committed step in protectin biosynthesis
- Specialized pro-resolving mediators (SPMs) — protectins are one of four major SPM families
- Resolvins — related SPM family from EPA and DHA; complementary resolution functions
- Maresins — related SPM family from DHA via 12-LOX; synergistic tissue repair effects
- Lipoxins (LX) — arachidonic acid-derived SPMs; protectins evolved later (require 22-carbon PUFA)
- Eicosanoid switch — shift from pro-inflammatory (LTB4, PGE2) to pro-resolving mediators (protectins)
- Efferocytosis — protectins enhance macrophage clearance of apoptotic neutrophils via C1q, Annexin-1, and phosphatidylserine recognition
- GPR37 — primary protectin receptor; mutations linked to Parkinson's disease
- Neuroinflammation — protectins suppress microglial activation and prevent secondary neuronal damage
- COX-2 acetylation — aspirin-modified COX-2 generates aspirin-triggered protectins (ATPs)
- Omega-3 fatty acids — dietary source; omega-3 index <4% predicts SPM insufficiency
- FADS2 — encodes Δ6-desaturase; polymorphisms reduce DHA synthesis and protectin production
- NF-κB — transcription factor suppressed by protectin signaling; reduces pro-inflammatory gene expression
- Alzheimer's Disease — hippocampal NPD1 deficiency contributes to chronic neuroinflammation and synaptic loss
- Stroke — endogenous NPD1 synthesis in peri-infarct zones limits infarct expansion
- Microglia — primary CNS cells responding to protectins; shift from M1 to M2-like phenotype
- neutrophil — protectins block transendothelial migration and shorten neutrophil lifespan
- IL-6 — pro-inflammatory cytokine downregulated by protectin signaling
- BDNF — brain-derived neurotrophic factor; NPD1 preserves BDNF-dependent synaptic plasticity
- Resolution interval (R_i) — protectins shorten R_i by accelerating neutrophil clearance and debris removal
- Aspirin — low-dose aspirin potentiates protectin biosynthesis via COX-2 acetylation
- RORα — nuclear receptor mediating genomic protectin effects; regulates circadian and metabolic genes
- HIF-1 — hypoxia-inducible factor; NPD1 stabilizes HIF-1α under ischemic stress, promoting neuroprotection
- Apoptosis — protectins prevent neuronal apoptosis via Bcl-2 upregulation and caspase-3 inhibition
- Mitochondrial dysfunction — NPD1 preserves mitochondrial membrane potential and prevents cytochrome-c release